Traws Pharma, Inc. carries no debt; cash flow comfortably covers obligations.

Traws Pharma, Inc.'s free cash flow has increased -30.28% from $-29.79M last year to $-20.77M, signaling increasing performance

Traws Pharma, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Traws Pharma, Inc. has insufficient data to evaluate this check.

Traws Pharma, Inc. has a net cash position, so leverage is healthy.

Traws Pharma, Inc. carries no debt; interest obligations are fully covered.

Traws Pharma, Inc.'s profit margin has increased (-100.00%) in the last year from -24.19K% to 0.00%, signaling increasing performance

Traws Pharma, Inc.'s short-term liabilities of $11.15M exceed its short-term assets of $7.98M, signaling financial risk

Traws Pharma, Inc.'s return on assets of -178.40% is lower than the 5.00% threshold, indicating inefficient asset utilization

Traws Pharma, Inc.'s return on equity of 489.90%, is higher than 15.00%, indicating good performance

Traws Pharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Traws Pharma, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Traws Pharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Traws Pharma, Inc. has negative free cash flow, indicating cash burn

Traws Pharma, Inc.'s yearly earnings has increased -116.77% since last year from $-54.67M to $9.17M, signaling increasing performance

Traws Pharma, Inc.'s yearly revenue has increased 1.23M% since last year from $226.00K to $2.79B, signaling increasing performance

ROIC 283.33% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Traws Pharma, Inc.'s 3-year revenue CAGR of 131.12% is positive, indicating growing revenue over the past 3 years

Traws Pharma, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Traws Pharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Traws Pharma, Inc. is undervalued relative to its fair value price of 444.71 based on Discounted Cash Flow model

Traws Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Traws Pharma, Inc. is undervalued relative to its fair value price of 462.45 based on EBITDA multiple model

Traws Pharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Traws Pharma, Inc. has insufficient data to evaluate this check.

Traws Pharma, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Traws Pharma, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Traws Pharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue